BR112022010687A2 - ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140 - Google Patents
ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140Info
- Publication number
- BR112022010687A2 BR112022010687A2 BR112022010687A BR112022010687A BR112022010687A2 BR 112022010687 A2 BR112022010687 A2 BR 112022010687A2 BR 112022010687 A BR112022010687 A BR 112022010687A BR 112022010687 A BR112022010687 A BR 112022010687A BR 112022010687 A2 BR112022010687 A2 BR 112022010687A2
- Authority
- BR
- Brazil
- Prior art keywords
- avian reovirus
- attenuated
- avian
- reovirus
- tenosynovitis
- Prior art date
Links
- 241001516406 Avian orthoreovirus Species 0.000 title abstract 5
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 206010003274 Arthritis viral Diseases 0.000 abstract 2
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 2
- 208000004760 Tenosynovitis Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000271566 Aves Species 0.000 abstract 1
- 241000272496 Galliformes Species 0.000 abstract 1
- 241000702263 Reovirus sp. Species 0.000 abstract 1
- 244000144977 poultry Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12061—Methods of inactivation or attenuation
- C12N2720/12064—Methods of inactivation or attenuation by serial passage
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
CEPAS DE REOVÍRUS AVIÁRIO ATENUADO 94826 C140 E 96139 C140. Isolados atenuados de reovírus aviários associados a artrite viral/tenossinovite em aves domésticas são apresentados, incluindo a cepa de reovírus aviário 94826 C140 depositada na ATCC sob a designação de patente PTA-126077 e a progênie ou os derivados da mesma e a cepa de reovírus aviário 96139 C140 depositada na ATCC sob a designação de patente PTA-126078 e a progênie ou os derivados da mesma. Composições e métodos para administrar os isolados ou as composições como vacinas para o controle da artrite viral/tenossinovite induzida por reovírus em aves da ordem Galliformes também são apresentados.ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140. Attenuated isolates of avian reoviruses associated with viral arthritis/tenosynovitis in poultry are presented, including the avian reovirus strain 94826 C140 deposited with the ATCC under patent designation PTA-126077 and the progeny or derivatives thereof and the avian reovirus strain 96139 C140 filed with the ATCC under patent designation PTA-126078 and progeny or derivatives thereof. Compositions and methods for administering the isolates or the compositions as vaccines for the control of viral arthritis/reovirus-induced tenosynovitis in birds of the order Galliformes are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962942426P | 2019-12-02 | 2019-12-02 | |
PCT/US2020/062651 WO2021113206A1 (en) | 2019-12-02 | 2020-12-01 | Attenuated avian reovirus strains 94826 c140 and 96139 c140 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022010687A2 true BR112022010687A2 (en) | 2022-08-23 |
Family
ID=76221714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022010687A BR112022010687A2 (en) | 2019-12-02 | 2020-12-01 | ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230000972A1 (en) |
EP (1) | EP4069289A4 (en) |
JP (1) | JP2023504225A (en) |
CN (1) | CN114828883A (en) |
BR (1) | BR112022010687A2 (en) |
MX (1) | MX2022006546A (en) |
WO (1) | WO2021113206A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116478937B (en) * | 2023-06-12 | 2023-08-18 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Gene III avian reovirus variant and application thereof in preparing vaccine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3099789A4 (en) | 2014-01-29 | 2017-09-13 | University Of Georgia Research Foundation, Inc. | Avian reovirus vaccines |
WO2017210262A1 (en) * | 2016-06-02 | 2017-12-07 | Steven Baranowitz | Prevention and treatment of viral infections |
-
2020
- 2020-12-01 US US17/779,811 patent/US20230000972A1/en active Pending
- 2020-12-01 JP JP2022559462A patent/JP2023504225A/en active Pending
- 2020-12-01 BR BR112022010687A patent/BR112022010687A2/en unknown
- 2020-12-01 WO PCT/US2020/062651 patent/WO2021113206A1/en unknown
- 2020-12-01 CN CN202080084537.4A patent/CN114828883A/en active Pending
- 2020-12-01 MX MX2022006546A patent/MX2022006546A/en unknown
- 2020-12-01 EP EP20896013.8A patent/EP4069289A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023504225A (en) | 2023-02-01 |
EP4069289A1 (en) | 2022-10-12 |
CN114828883A (en) | 2022-07-29 |
EP4069289A4 (en) | 2023-11-29 |
WO2021113206A1 (en) | 2021-06-10 |
MX2022006546A (en) | 2022-07-01 |
US20230000972A1 (en) | 2023-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BARBERIS et al. | History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines | |
BR112019023758A2 (en) | newcastle disease virus and its uses | |
BR112012004806B8 (en) | immunogenic compositions that include modulators of tlr activity, method to increase the effectiveness of said composition and use | |
BR112012033227A2 (en) | glucagon analogs | |
BRPI0707300A8 (en) | VACCINE AGAINST DIVIDED INFLUENZA VIRION OR PURIFIED SURFACE ANTIGEN AND METHOD FOR THE PREPARATION OF AN IMMUNOGENIC COMPOSITION | |
BR112016003317A2 (en) | avian adenovirus vaccine | |
BR112022010687A2 (en) | ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140 | |
EA201792487A1 (en) | COMPOSITIONS OF HYDROXYPROPYL-BET-CYCLODEXTRINS AND METHODS | |
BR112017011552A2 (en) | fgf21 derivatives and their use | |
BR112017000519A2 (en) | "immunogenic composition, and method for protecting a mammal against meningococcal infection" | |
BR112021024127A2 (en) | modified adenovirus | |
CO2021017317A2 (en) | Safe and invisible cells for the immune system | |
CN107208071B (en) | Attenuated live vaccines for influenza virus | |
BR112021012616A2 (en) | Ergothioneine-producing strain and method for screening it | |
BR112014011443A2 (en) | lactic acid bacteria and their use as feed supplements for poultry | |
BR112017023147A2 (en) | azabenzimidazoles and their use as ampule receptor modulators | |
BRPI0516542A (en) | composition of vaccine effective in preventing or ameliorating infection with avian influenza virus; method to prevent or improve the outbreak of infection by avian influenza virus | |
BR112017013999A2 (en) | "composition derived from a bifidobacterium" | |
ZA202211004B (en) | 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus | |
BR112023020077A2 (en) | OXOISOINDOLINE COMPOUNDS REPLACED BY PYRIDINYL | |
BR112020004935A2 (en) | Pharmaceutical composition comprising an antibody which specifically binds to the n-terminus of lysyl-tRNA synthetase as an active ingredient for the prevention or treatment of cell migration-related disease | |
BR112022019207A2 (en) | VACCINE COMPOSITIONS FOR CORONA VIRUSES AND METHODS OF THEIR USE | |
BR112016017242A2 (en) | LENTIVIRAL VECTORS TO GENERATE IMMUNE RESPONSES AGAINST HUMAN T-LYMPHOTROPIC VIRUS TYPE 1 | |
BR112021024810A2 (en) | Compound, pharmaceutical composition, use of a compound, method for the treatment or prophylaxis of cancer and method for the treatment or prophylaxis of non-small cell lung cancer | |
AR048429A1 (en) | ISOLATED ANTIGENIC AND VACCINES OF INFECTIOUS BURSITIS VIRUS |